Palo Alto Investors LLC Continues to Hold Stake in Cempra, Inc. (CEMP)
Palo Alto Investors LLC maintained its position in shares of Cempra, Inc. (NASDAQ:CEMP) during the second quarter, according to the company in its most recent filing with the SEC. The firm owned 340,320 shares of the biotechnology company’s stock at the end of the second quarter. Palo Alto Investors LLC owned about 0.65% of Cempra worth $1,565,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of CEMP. Pennsylvania Trust Co bought a new position in Cempra during the 2nd quarter worth approximately $7,784,000. Renaissance Technologies LLC grew its position in Cempra by 175.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,680,500 shares of the biotechnology company’s stock worth $6,302,000 after acquiring an additional 1,069,300 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Cempra by 1,279.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 753,402 shares of the biotechnology company’s stock worth $3,466,000 after acquiring an additional 698,771 shares during the last quarter. Bogle Investment Management L P DE grew its position in Cempra by 607.0% during the 1st quarter. Bogle Investment Management L P DE now owns 709,518 shares of the biotechnology company’s stock worth $2,660,000 after acquiring an additional 609,168 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in Cempra by 61.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 461,451 shares of the biotechnology company’s stock worth $2,123,000 after acquiring an additional 175,874 shares during the last quarter. Institutional investors and hedge funds own 49.75% of the company’s stock.
CEMP has been the topic of several recent research reports. Stifel Nicolaus restated a “hold” rating and set a $4.00 price target on shares of Cempra in a research report on Thursday, August 10th. Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $4.00 in a research report on Thursday, August 10th. Zacks Investment Research upgraded Cempra from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Friday, August 11th. Finally, Jefferies Group LLC restated a “hold” rating and set a $3.00 price target on shares of Cempra in a research report on Thursday, September 14th. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Cempra currently has an average rating of “Hold” and a consensus price target of $10.00.
ILLEGAL ACTIVITY NOTICE: “Palo Alto Investors LLC Continues to Hold Stake in Cempra, Inc. (CEMP)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/palo-alto-investors-llc-continues-to-hold-stake-in-cempra-inc-cemp.html.
Cempra, Inc. (NASDAQ CEMP) traded up 0.000% on Thursday, hitting $3.275. The stock had a trading volume of 303,187 shares. The stock’s 50-day moving average is $3.06 and its 200 day moving average is $3.75. The firm’s market capitalization is $171.96 million. Cempra, Inc. has a 1-year low of $2.55 and a 1-year high of $24.48.
Cempra (NASDAQ:CEMP) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. The company’s quarterly revenue was down 74.9% on a year-over-year basis. On average, equities research analysts predict that Cempra, Inc. will post ($1.01) earnings per share for the current fiscal year.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Stock Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related stocks with our FREE daily email newsletter.